FDA Inspection 1255022 — Aopline Health Industry Technology (Guangzhou) Co., Ltd.
The FDA completed an inspection of Aopline Health Industry Technology (Guangzhou) Co., Ltd. on November 8, 2024 in Zengcheng, Guangzhou. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- November 8, 2024
- Fiscal Year
- 2025
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Zengcheng, Guangzhou (China)